Evidence map›Paper›PMID 38007418›Full record

ArticleBMC cancer2023

Accurate prediction of HCC risk after SVR in patients with hepatitis C cirrhosis based on longitudinal data.

Yanzheng Zou, Ming Yue, Linna Jia, Yifan Wang, Hongbo Chen, Amei Zhang, Xueshan Xia, Wei Liu, Rongbin Yu, Sheng Yang and 1 more

Open access · goldAbstract read
In one paragraph

Article in BMC cancer, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
11citing papers in PubMed, 1 pooled it
2.7field-weighted citation impact, top 9% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

11 citing papers in PubMed, 1 synthesis or guideline pooled it, 13 citations in OpenAlex.

  1. Pooled it
  2. Article
  3. Article
  4. Observational
  5. Review
  6. Review
  7. Article
  8. Observational
  9. Review
  10. Article
  11. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 5 institutions in 1 country.

Yanzheng Zou *Department of Epidemiology, Center for Global Health, School of Public Health, Nanjing Medical University, Nanjing, 211166, China.
Ming Yue *Department of Infectious Diseases, The First Affiliated Hospital of Nanjing Medical University, Nanjing, China.
Linna JiaDepartment of Epidemiology, Center for Global Health, School of Public Health, Nanjing Medical University, Nanjing, 211166, China.
Yifan WangDepartment of Infectious Disease, Jurong Hospital Affiliated to Jiangsu University, Jurong, China.
Hongbo ChenDepartment of Infectious Disease, Jurong Hospital Affiliated to Jiangsu University, Jurong, China.
Amei ZhangFaculty of Life Science and Technology, Kunming University of Science and Technology, Yunnan, China.
Xueshan XiaFaculty of Life Science and Technology, Kunming University of Science and Technology, Yunnan, China.
Wei LiuDepartment of Epidemiology, Center for Global Health, School of Public Health, Nanjing Medical University, Nanjing, 211166, China.
Rongbin YuDepartment of Epidemiology, Center for Global Health, School of Public Health, Nanjing Medical University, Nanjing, 211166, China. rongbinyu@njmu.edu.cn.
Sheng YangDepartment of Biostatistics, Center for Global Health, School of Public Health, Nanjing Medical University, Nanjing, 211166, China. yangsheng@njmu.edu.cn.
Peng HuangDepartment of Epidemiology, Center for Global Health, School of Public Health, Nanjing Medical University, Nanjing, 211166, China. huangpeng@njmu.edu.cn.
Nanjing Medical University · CNJiangsu University · CNJiangsu Province Hospital · CNKunming Medical University · CNKunming University of Science and Technology · CN

Funding

Nanjing Important Science & Technology Specific Projects 2021-11005National Natural Science Foundation of China 82273691National Natural Youth Science Foundation of China 81703273Natural Science Foundation of Jiangsu Province BK20190106Priority Academic Program Development of Jiangsu Higher Education Institutions PAPD
6 · The paper itself

Abstract

backgroundMost existing predictive models of hepatocellular carcinoma (HCC) risk after sustained virologic response (SVR) are built on data collected at baseline and therefore have limited accuracy. The current study aimed to construct an accurate predictive model incorporating longitudinal data using a novel modeling strategy. The predictive performance of the longitudinal model was also compared with a baseline model.

methodsA total of 400 patients with HCV-related cirrhosis who achieved SVR with direct-acting antivirals (DAA) were enrolled in the study. Patients were randomly divided into a training set (70%) and a validation set (30%). Informative features were extracted from the longitudinal variables and then put into the random survival forest (RSF) to develop the longitudinal model. A baseline model including the same variables was built for comparison.

resultsDuring a median follow-up time of approximately 5 years, 25 patients (8.9%) in the training set and 11 patients (9.2%) in the validation set developed HCC. The areas under the receiver-operating characteristics curves (AUROC) for the longitudinal model were 0.9507 (0.8838-0.9997), 0.8767 (0.6972,0.9918), and 0.8307 (0.6941,0.9993) for 1-, 2- and 3-year risk prediction, respectively. The brier scores of the longitudinal model were also relatively low for the 1-, 2- and 3-year risk prediction (0.0283, 0.0561, and 0.0501, respectively). In contrast, the baseline model only achieved mediocre AUROCs of around 0.6 (0.6113, 0.6213, and 0.6480, respectively).

conclusionsOur longitudinal model yielded accurate predictions of HCC risk in patients with HCV-relate cirrhosis, outperforming the baseline model. Our model can provide patients with valuable prognosis information and guide the intensity of surveillance in clinical practice.

Indexed as

Carcinoma, HepatocellularHepatitis CHepatitis C, ChronicLiver NeoplasmsAntiviral AgentsHepacivirusHumansLiver CirrhosisSustained Virologic ResponseAntiviral AgentsDirect-acting antiviralsHepatocellular carcinomaLongitudinal studyMachine learningPredictive models

Identifiers

PMID38007418
PMCPMC10676612
OpenAlexW4388996988

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.